Takeda hoping for third time lucky as it resubmits alogliptin and combo in US
This article was originally published in Scrip
Executive Summary
Takeda has re-filed new drug applications in the US for its antidiabetic alogliptin and a fixed-dose combination of the dipeptidyl peptidase IV inhibitor with pioglitazone (Takeda's Actos), hoping that this time it will be able to satisfy the agency's concerns after years of delays.